Navigation Links
eResearchTechnology Reports Third Quarter 2008 Results
Date:10/30/2008

Q3 2008 Net Revenues - $33.9 million vs. $24.0 million in Q3 2007 - an

increase of 41.5% Q3 2008 Diluted Net Income per Share - $0.13 vs. $0.07 in Q3 2007 - an

increase of 85.7%

Q3 2008 Operating Income margin of 31.1% vs. 22.4% in Q3 2007

Q3 2008 New Bookings of $43.0 million vs. $35.5 million in Q3 2007

PHILADELPHIA, Oct. 30 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), (Nasdaq: ERES), a leading provider of centralized ECG and eClinical technology, ePRO and other services to the pharmaceutical, biotechnology, medical device and related industries, announced today results for the third quarter and nine-month period ended September 30, 2008.

Financial highlights for the third quarter of 2008 were:

-- Net revenues were $33.9 million, a 41.5% increase from the third quarter of 2007;

-- Diluted net income per share was $0.13, an 85.7% increase from the third quarter of 2007;

-- Gross margin was $19.1 million for a gross margin percentage of 56.3%, compared to 48.0% in the third quarter of 2007. The gross margin included the impact of the operating results of Covance Cardiac Safety Services (CCSS) and the integration of CCSS into eRT. CCSS generated net revenues of $1.9 million from acquired backlog during the third quarter while incurring costs of revenue of $1.7 million, including depreciation and amortization of acquired assets of $680,000;

-- Operating income was $10.5 million, a 96.8% increase from the third quarter of 2007. Operating income margin percentage was 31.1%, compared to 22.4% in the third quarter of 2007. Operating income included a loss of $505,000 from the operations of CCSS and the integration of CCSS into eRT;

-- The Company's tax rate was 35.8% for the third quarter of 2008, which included the effect of certain tax benefits realized, compared to 37.7% for the third quarter of 2007;

-- New bookings were $43.0 million compared to $35.5 million for the third quarter of 2007, an increase of 21.1%;

-- New bookings included seven new Thorough ECG study agreements, valued at an average of slightly greater than $1 million each;

-- The backlog was $159.2 million, compared to $157.9 million at June 30, 2008.

-- The book-to-bill ratio was 1.3 in the third quarter of 2008, compared to 1.4 in the second quarter of 2008; and

-- eRT ended the third quarter with $62.4 million in cash, cash equivalents, and investments, an increase of $6.5 million from $55.9 million at June 30, 2008. For the three months ended September 30, 2008, net cash provided by operating activities was $8.8 million.

Other recent highlights:

-- The cancellation rate was an annualized 19.6% as compared to 18.1% in the second quarter of 2008. The cancellation rate is calculated as the sum of the actual value of study cancellations plus studies that are completed at amounts under the original contracted amount divided by beginning backlog. The increase in the cancellation rate was caused by a number of long-term projects ending without completion of the full number of contracted ECGs.

-- We successfully completed the integration of the CCSS acquisition with the complete transfer of all operating activities from the CCSS Reno facility into our operations in Philadelphia and Peterborough, UK; and

-- We are on track for the move of our corporate headquarters (and US- based core lab) in Philadelphia to a larger facility, also in Philadelphia, by the end of 2008.

Financial highlights for the first nine months of 2008:

-- For the nine months ended September 30, 2008, the Company reported net revenues of $103.1 million compared to $69.8 million for the nine months ended September 30, 2007, an increase of 47.7%;

-- Net income was $19.3 million, or $0.37 per diluted share, for the nine months ended September 30, 2008 compared to net income of $10.1 million, or $0.20 per diluted share, for the nine months ended September 30, 2007, an increase of 91.6%;

-- Bookings for the nine months ended September 30, 2008 were $142.1 million, which are $3.4 million higher than the bookings of $138.6 recorded for the entire year 2007;

-- The Company's gross margin percentage for the nine months ended September 30, 2008 was 55.3% compared to 49.9% for the nine months ended September 30, 2007. Operating income margin for the nine months ended September 30, 2008 was 28.9% compared to 21.1% for the nine months ended September 30, 2007;

-- Revenues from acquired backlog of CCSS were $8.2 million and cost of revenues were $7.2 million for the nine months ended September 30, 2008. Operating income during this period included a loss of $2.2 million from the operations of CCSS and the integration of CCSS into eRT;

-- The Company's tax rate was 37.1% for the nine months ended September 30, 2008 compared to 38.5% for the nine months ended September 30, 2007; and

-- For the nine months ended September 30, 2008, cash provided by operating activities was $26.8 million.

"We continue to be pleased with our results through the third quarter of 2008," commented Dr. Michael McKelvey, President and CEO of eRT. "Our $33.9 million of revenue for the third quarter reflected the expected sequential decrease from our record $35.5 million in the second quarter 2008 due to slower activity in the summer months and a working down of the CCSS backlog. Through the nine months ending September 30, 2008, revenue, bookings, and net income have all exceeded the levels achieved in all of 2007. As an example, net income through the first nine months of 2008 was 26.8% higher than in the entire 2007 year. We were able to increase our third quarter operating income margin to 31.1% from 30.3% in the second quarter of 2008. Net income for the third quarter was $6.9 million, an increase of 87.0% from $3.7 million for the third quarter of 2007."

"We continue to execute very well on our projects," continued Dr. McKelvey. "We completed the integration of the CCSS acquisition, which was a tremendous accomplishment by our staff. Our sales force reports a healthy pipeline of new opportunities, reflecting the continued emphasis on cardiac safety and eRT's reputation for quality, medical and scientific leadership, project execution, and technology innovation. The pricing environment continues to be stable. In the current economic and financial environment, we feel that our strong balance sheet and cash flow, the continued importance of cardiac safety in clinical trials, and our established reputation for quality, project management, and cost-effective performance will be important contributors to our business going forward."

2008 Guidance

The Company issued guidance for the full year and fourth quarter of 2008. For the full year 2008, the Company is narrowing its revenue range and expects revenue of between $134.0 million and $137.0 million. The company is raising its guidance for diluted net income per share to between $0.47 to $0.50 for the full year 2008. The company's revenue guidance for the fourth quarter is between $31.0 to $34.0 million, and its guidance for diluted net income per share for the fourth quarter is between $0.10 and $0.13.

Conference Call

Dr. McKelvey and Keith Schneck, the Company's Chief Financial Officer, will hold a conference call to discuss these results. The conference call will take place at 5:00 p.m. EDT on October 30, 2008. Interested participants should call 1-866-277-1181 when calling within the United States or 617-597- 5358 when calling internationally. Please use pass code 54904519. There will be a playback available until November 6, 2008. To listen to the playback, please call 1-888-286-8010 when calling within the United States or 617-801- 6888 when calling internationally. Please use pass code 17782796 for the replay.

This call is being webcast by Thomson Financial and can be accessed at eRT's web site at http://www.eRT.com. The webcast may also be accessed at Thomson's Institutional Investor website at http://phx.corporate-ir.net/playerlink.zhtml?c=119164&s=wm&e=1991822 . The webcast can be accessed for up to one year on either site.

About eResearchTechnology, Inc.

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.eRT.com) is a provider of technology and services to the pharmaceutical, biotechnology, and medical device industries on a global basis. The Company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The Company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including but not limited to 2008 financial guidance, involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

eResearchTechnology, Inc. and Subsidiaries

Consolidated Statements of Operations

(in thousands, except per share amounts)

(unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2007 2008 2007 2008

Net revenues:

Licenses $651 $891 $2,013 $2,386

Services 16,453 24,857 47,982 77,510

Site support 6,867 8,182 19,794 23,179

Total net revenues 23,971 33,930 69,789 103,075

Costs of revenues:

Cost of licenses 70 179 199 549

Cost of services 7,567 9,951 21,590 30,948

Cost of site support 4,831 4,698 13,143 14,565

Total costs of revenues 12,468 14,828 34,932 46,062

Gross margin 11,503 19,102 34,857 57,013

Operating expenses:

Selling and marketing 2,487 3,126 8,079 10,259

General and

administrative 2,527 4,254 8,915 13,728

Research and development 1,128 1,173 3,155 3,223

Total operating expenses 6,142 8,553 20,149 27,210

Operating income 5,361 10,549 14,708 29,803

Other income, net 584 251 1,703 922

Income before income taxes 5,945 10,800 16,411 30,725

Income tax provision 2,239 3,870 6,318 11,389

Net income $3,706 $6,930 $10,093 $19,336

Basic net income per share $0.07 $0.14 $0.20 $ 0.38

Diluted net income

per share $0.07 $0.13 $0.20 $ 0.37

Shares used to calculate

basic net income

per share 50,594 50,856 50,430 50,743

Shares used to calculate

diluted net income per

share 51,829 52,180 51,681 52,085

eResearchTechnology, Inc. and Subsidiaries

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

December 31, 2007 September 30, 2008

ASSETS (unaudited)

Current assets:

Cash and cash equivalents $38,082 $62,326

Short-term investments 8,797 50

Accounts receivable, net 26,718 32,827

Prepaid income taxes 743 -

Prepaid expenses and other 3,087 4,132

Deferred income taxes 901 1,017

Total current assets 78,328 100,352

Property and equipment, net 33,347 27,345

Goodwill 30,908 33,544

Intangible assets 3,849 2,496

Deferred income taxes 1,011 1,999

Other assets 253 589

Total assets $147,696 $166,325

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable $3,505 $3,882

Accrued expenses 12,103 8,481

Income taxes payable 2,352 2,498

Current portion of capital lease

obligations 1,097 60

Deferred revenues 13,905 14,377

Total current liabilities 32,962 29,298

Capital lease obligations, excluding

current portion 48 -

Other liabilities 1,174 1,075

Total liabilities 34,184 30,373

Stockholders' equity:

Preferred stock-$10.00 par value,

500,000 shares authorized, none

issued and outstanding - -

Common stock-$.01 par value,

175,000,000 shares authorized,

58,870,291 and 59,138,090 shares

issued, respectively 589 591

Additional paid-in capital 87,957 92,313

Accumulated other comprehensive

income 1,679 425

Retained earnings 85,477 104,813

Treasury stock, 8,247,119 shares

at cost (62,190) (62,190)

Total stockholders' equity 113,512 135,952

Total liabilities and

stockholders' equity $147,696 $166,325

eResearchTechnology, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

Nine Months Ended September 30,

2007 2008

Operating activities:

Net income $10,093 $19,336

Adjustments to reconcile net

income to net cash provided

by operating activities:

Depreciation and amortization 11,066 12,519

Cost of sales of equipment 1,004 717

Provision for

uncollectible accounts - 60

Share-based compensation 1,576 1,966

Deferred income taxes 482 (1,151)

Changes in operating assets

and liabilities excluding CCSS

acquisition:

Accounts receivable (3,777) (6,601)

Prepaid expenses and other (595) (1,560)

Accounts payable (1,888) 357

Accrued expenses 1,500 (540)

Income taxes 2,267 931

Deferred revenues 995 747

Net cash provided by

operating activities 22,723 26,781

Investing activities:

Purchases of property and equipment (10,066) (6,966)

Purchases of investments (50,108) -

Proceeds from sales of investments 48,617 8,747

Payments for acquisition - (4,964)

Net cash used in

investing activities (11,557) (3,183)

Financing activities:

Repayment of capital lease obligations (1,962) (1,085)

Proceeds from exercise of stock options 1,600 1,502

Stock option income tax benefit 628 839

Net cash provided by

financing activities 266 1,256

Effect of exchange rate changes on cash 269 (610)

Net increase in cash and cash equivalents 11,701 24,244

Cash and cash equivalents, beginning

of period 15,497 38,082

Cash and cash equivalents, end of period $27,198 $62,326


'/>"/>
SOURCE eResearchTechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved


Related biology technology :

1. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
2. eResearchTechnology to Present at the UBS Global Healthcare Services Conference 2008 on February 11th
3. eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008
4. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
5. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
6. eResearchTechnology, Inc. to Announce 2008 First Quarter Results on May 5, 2008
7. eResearchTechnology to Present at the Deutsche Bank 33rd Annual Healthcare Conference on May 7th 2008
8. eResearchTechnology Reports First Quarter 2008 Results
9. eResearchTechnology Announces Resignation of its CFO
10. eResearchTechnology to Present at the FBR 12th Annual Spring Investor Conference on May 28th 2008
11. eResearchTechnology Names New Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 09, 2016 , ... Creation Technologies, leading global provider of ... Customer Rating Award from Circuits Assembly , today announced its milestone achievement of ... Mexico and China. , The EMS provider, known in the EMS industry for ...
(Date:2/9/2016)... ... February 08, 2016 , ... Date and time: ... Institute at the Pennsylvania Biotechnology Center of Bucks County, 3805 Old Easton Road, ... College (TCMC) will hold an open house for participants to learn about a ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... Tunnell Consulting, ... Based in Paris, he will focus on acquiring new accounts and work closely ... , “Fred brings to our European clients more than 15 years ...
(Date:2/9/2016)... ... February 09, 2016 , ... PharmApprove announced ... the National Organization for Rare Disorders (NORD). Dorman will lead PharmApprove efforts to ... heard throughout the drug regulatory review process. , “Adding Diane Dorman is just ...
Breaking Biology Technology:
(Date:2/3/2016)... 3, 2016 Vigilant Solutions announces today that ... Missouri solved two recent hit-and-run ... data from Vigilant Solutions. Brian Wenberg ... the victim was walking out of a convenience store and witnessed an elderly ... his vehicle, striking his vehicle and leaving the scene.  ...
(Date:2/2/2016)... Feb. 2, 2016 Technology Enhancements Accelerate Growth of ... of the digital and computed radiography markets in ... and Indonesia (TIM). It provides ... size, as well as regional market drivers and restraints. ... market penetration and market attractiveness, both for digital and ...
(Date:2/1/2016)... smart wallet ( www.wocketwallet.com ) announces the launch of a new video ... Las Vegas , where Joey appeared at the Wocket ... Vegas , where Joey appeared at the Wocket booth to meet ... filmed at the Consumer Electronics Show (CES2016) in Las Vegas ... greet fans. --> --> The ...
Breaking Biology News(10 mins):